tbuckley/cabot-search huggingface dataset:
OP0093 Does “Pain Elsewhere” Influence The Association between Knee Structural Pathology and Knee Pain?
Authors: F. Pan, D. Aitken, J. Tian, F. Cicuttini, T. Winzenberg, C. Ding, G. Jones
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> The association between structural abnormalities and knee pain remains controversial. It may be that the association is weaker in those with generalized pain compared to localized pain. <h3>Objectives</h3> To determine the effect of pain at other sites on the association between knee structural pathology and knee pain in knee osteoarthritis (OA). <h3>Methods</h3> 1099 participants (average age 63 years; range 51 to 81 years) from the population-based Tasmanian Older Adult Cohort study were studied. Presence of pain (yes/no) at the neck, back, hands, shoulders, hips, knees and feet was assessed by questionnaire. T1-weighted or T2-weighted fat saturated MRI of the right knee was performed to measure cartilage defects, bone marrow lesions (BMLs) and effusion. Osteophytes and joint space narrowing (JSN) were assessed by X-ray. Data were analyzed using multi-nominal logistic regression with adjustment for potential confounders including age, sex, body mass index, physical activity, smoking history and pain medication. <h3>Results</h3> Knee pain only, knee plus any other site pain, and any other site pain were present in 3%, 44% and 41% of participants respectively. In multivariable analyses, knee pain only was strongly associated with the presence of cartilage defects (OR 16.96, 95% CI 4.03 to 71.32), BMLs (OR 3.27, 95% CI 1.01 to 10.53), effusion (OR 3.52, 95% CI 1.06 to 11.68) and osteophytes (OR 8.22, 95% CI 2.10 to 32.27). There were significant but weaker associations with knee pain plus any other site pain (OR=3.03 to 3.38, all P&lt;0.05). Any other site pain was not found to be associated with any knee structural abnormalities. There was a dose-response relationship between number of knee structural abnormalities, and knee pain only and knee plus any other site pain (both P for trend≤0.002). <h3>Conclusions</h3> Knee structural abnormalities are more strongly associated with localized knee pain than generalized pain, suggesting that pain elsewhere may influence the association of knee structural pathology and knee pain. The underlying mechanism may be due to central sensitization implicated in generalized pain which is no longer coupled to peripheral stimuli. Implication of this finding for clinicians and researchers is that pain at other sites needs to be considered while developing an approach to slow OA progression and alleviate symptom by targeting structural abnormalities. <h3>Disclosure of Interest</h3> None declared
FRI0105 Low Thoracic Bone Mineral Density and Glucocorticoid Are Risk Factors for Clinical Fractures in Patients with Rheumatoid Arthritis: Five-Year Findings of The Tomorrow Study: Table 1.
Authors: Y. Yamada, K. Inui, K. Mamoto, T. Okano, Y. Sugioka, M. Tada, T. Koike, H. Nakamura
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Patients with rheumatoid arthritis (RA) who have muscle weakness and stiff or painful joints might be at increased risk of falls and fracture. <h3>Objectives</h3> The present study aimed to prospectively determine the incidence of clinical fractures and associated risk factors in patients with RA who participated in the TOMORROW study (UMIN000003876) that started in 2010. <h3>Methods</h3> We evaluated anthropometric parameters, bone mineral density (BMD), disease activity, RA medication, and the incidence of clinical fractures over a five-year period in 202 patients with RA (mean age, 58.6 y; medication with biological agents, 54.9%) and 202 age- and sex-matched healthy volunteers (controls; mean age, 57.4 y). We compared the incidence of clinical fractures between patients and controls between 2010 and 2015 and analyzed associated risk factors in the patients using multivariate regression analysis. <h3>Results</h3> The incidence of clinical fractures did not significantly differ between patients with RA (0.042/person-years; py) and controls (0.034/py) within the five-year period (p=0.35). Fractures sites also did not significantly differ between the two groups. Multivariate logistic regression analysis adjusted for fracture risk factors including age, sex, smoking, and body mass index revealed that low BMD at the thoracic vertebrae (&lt;0.7 g/cm<sup>2</sup>) was significantly associated with the incidence of clinical fractures (odds ratio [OR], 2.95) in all participants group (Table 1). Although medication with glucocorticoid (GC) at entry was also a significant risk factor for fractures (OR, 2.58), RA morbidity was not (Table 1). Among patients with RA, low BMD at the thoracic vertebrae (&lt;0.7 g/cm<sup>2</sup>) was the most prominent risk factor for fractures (OR, 4.44; Table 1). Additionally, medication with GC at entry (OR, 2.58) was a significant risk factor for fractures in the patients. A mean GC dose of ≥2 mg/day during the five-year period increased risk for fractures in the patients (OR, 3.48; Table 1). <h3>Conclusions</h3> The incidence of clinical fractures did not significantly differ between patients with RA and controls during a period of five years. Low BMD at the thoracic vertebrae and low GC doses are apparently significantly associated with an increased frequency of fractures among patients with RA. <h3>Disclosure of Interest</h3> None declared
EPID-19ASSOCIATION STUDY BETWEEN HFE POLYMORPHISMS AND SURVIVAL OF GLIOBLASTOMA PATIENTS IN TCGA DATABASE
Authors: Sang Lee, Junjia Zhu, Anna Salzberg, Dajiang Liu, James Connor
Journal: Neuro-Oncology (2015)

The HFE protein is involved in iron metabolism. There are two (H63D and C282Y) HFE polymorphisms. These HFE polymorphisms have been associated with increased risk in a number of cancers. Previously, we reported gender affects H63D or C282Y glioblastoma (GBM) patients' overall survival. To confirm our finding in a bigger sample size, we analyzed the frequency of HFE genotype and survival of GBM patients from The Cancer Genome Atlas (TCGA) database. There were 329 GBM samples data available for HFE genotype. Among 329 samples, 296 samples have both HFE genotype data and clinical information. The 296 samples consist of 264 White, 6 Asian, 18 Black, and 8 unknown. H63D and C282Y HFE polymorphisms are more common in Caucasians than other ethnicities, thus we used 264 samples (167 male and 97 female) data in the present study. The frequency of H63D and C282Y is approximately 26.5% (24.2% heterozygote and 2.3% homozygote) and 7.6% (6.8% heterozygote and 0.8% homozygote). This rate is similar with that for the general Caucasian population reported in the literature. The Kaplan-Meier survive curve for the 264 GBM samples revealed no difference between WT HFE and H63D and C282Y GBM patients. In addition, there is no difference in the survival of male/female GBM patients based on HFE genotype. To exclude any possibility of regional difference in survival/HFE genotype in our data analysis, we used single sample collection site data (n = 100) from 264 samples as well. However, we still did not observe any statistical difference between HFE genotype and overall survival including gender effect. In conclusion, HFE polymorphisms do not impact GBM patient's survival in TCGA data set of GBM. The present data and our previous data suggest that environment factors may affect the difference of survival length in GBM patients with HFE mutations.
Use of Pre-Emptive Donor Lymphocyte Infusions To Achieve Durable Remission Following Alemtuzumab Based Reduced Intensity Conditioning (RIC) Transplantation for AML or MDS.
Authors: ZiYi Lim, Laurence Pearce, Wendy Ingram, Rafael Duarte, Stephen Devereux, Antonio Pagliuca, Aloysius Ho, Ghulam Mufti
Journal: Blood (2005)
Impact of Molecular Mutations on Treatment Response to Hypomethylating Agents in MDS
Authors: Fabiola Traina, Anna M Jankowska, Valeria Visconte, Yuka Sugimoto, Hadrian Szpurka, Hideki Makishima, Andres Jerez, Christine L. O'Keefe, Mikkael A. Sekeres, Anjali S. Advani, Yogen Saunthararajah, Matt Kalaycio, Edward A. Copelan, Sara T. Olalla Saad, Jaroslaw P Maciejewski, Ramon V. Tiu
Journal: Blood (2011)
Z-Guggulsterone Downregulates Survivin and Induces Cell Death in Large B Cell Lymphoma Cells In Vitro.
Authors: Maria K. Angelopoulou, Konstantinos Lilakos, Vassilios Salpeas, Sotirios Sachanas, Penelope Korkolopoulou, Marina P. Siakantaris, Theodoros P. Vassilakopoulos, Panayiotis Panayiotidis, Gerassimos A. Pangalis
Journal: Blood (2006)
PWE-046 Comparison of Transient Elastography, Thrombocytopenia and Splenomegaly in Risk Assessment for The Presence of Oesophageal Varices: Abstract PWE-046 Table 1
Authors: W On, R Angelescu, A Abelidis, B Gurung, R Saravanan, G Berrisford, K Koss
Journal: Gut (2016)

<h3>Introduction</h3> The usage of transient elastography (TE) as a predictor of oesophageal varices has been widely studied. The formation of varices is the sequelae of portal hypertension (PH) which also manifest as splenomegaly leading to thrombocytopenia. We aim to establish the utility of TE in conjunction with PH in predicting varices. <h3>Methods</h3> Patients who underwent TE with the FibroScan® between June 2010 and January 2016 in our trust were identified. Only patients with a liver stiffness measurement (LSM) of &gt;11.5 kPa which is indicative of cirrhosis and had undergone an endoscopy were included. Thrombocytopenia was defined as a platelet count of &lt;150 x 10<sup>9</sup>/L and the presence of splenomegaly was identified from radiological investigations. A TE measurement of &gt;25 kPa has been regarded as the optimum cut-off value for predicting varices and is used in this study. <h3>Results</h3> 2,643 patients underwent TE during the time period. 372 patients had a LSM of &gt;11.5 kPa and of these patients, 157 patients underwent a gastroscopy. 41 patients (26.1%) had evidence of varices on gastroscopy. The sensitivity and specificity of TE in various combinations of PH in predicting varices are outlined in the table below. In total 46 out of our 157 patients with cirrhosis had TE &lt; 25 kPA, normal platelets and normal sized spleen on ultrasound scanning. Only 1 patient in that group (TE = 16.7 kPA) had early borderline oesophageal varices. <h3>Conclusion</h3> In our cohort of patients, a cut-off value of &gt;25 kPa on TE is a better predictor of varices (sensitivity 83%) than thrombocytopenia or splenomegaly. Assessment of LSM using TE in conjunction with thrombocytopenia and splenomegaly improves sensitivity further to 97%. Limiting screening endoscopy in patients with liver cirrhosis to those with any of those 3 criteria: TE &gt; 25 kPA, thrombocytopenia or splenomegaly, may reduce demand for endoscopy in that group of patients by 30%. <h3>Disclosure of Interest</h3> None Declared
Thrombocytopenia Is a Strong Predictor of All-Cause and AIDS-Specific Mortality in Women with HIV: The Women’s Interagency HIV Study.
Authors: C. Leigh Pearce, Wendy J. Mack, Alexandra M. Levine, Jay Gravink, Mardge H. Cohen, Edward L. Machtinger, Kathryn Anastos, Michael J. Silverberg, Mary A. Young, Howard Minkoff, D. Heather Watts
Journal: Blood (2004)
Initial Therapeutic Approach and Relationship with Clinical and Biological Characteristics at Diagnosis in 2418 Patients of the Registro Italiano Trombocitemie (RIT)
Authors: Luigi Gugliotta, Alessandra Iurlo, Gabriele Gugliotta, Alessia Tieghi, Anna Candoni, Daniele Cattaneo, Alessandra Ricco, Monia Lunghi, Elisa Rumi, Potito Rosario Scalzulli, Alfredo Dragani, Elisabetta Antonioli, Vincenzo Martinelli, Maria Luigia Randi, Nilla Maschio, Ercole De Biasi, Viviana Appolloni, Nicola Cantore, Raffaele Palmieri, Cristina Santoro, Nicola Polverelli, Angela Rago, Rossella R Cacciola, Maria Rosaria Villa, Katia Codeluppi, Ivana Pierri, Angelo Fama, Andrea Piccin, Bruno Martino, Nicola Vianelli, Serena Rupoli, Umberto Santoro, Rossella Miglio, Paola Monari, Maria Gabriella Mazzucconi
Journal: Blood (2014)
THU0325 Long-Term Outcome of Patients with Primary Antiphospholipid Syndrome: A Retrospective Multicenter Study
Authors: F. Dall'ara, M. Taraborelli, R. Reggia, M. Fredi, L. Andreoli, M. Gerosa, A. Hoxha, L. Massaro, M. Tonello, P. Cacoub, N. Costedoat-Chalumeau, F. Franceschini, P.L. Meroni, J.C. Piette, A. Ruffatti, G. Valesini, E.N. Harris, A. Tincani
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Data on the long-term outcome in primary antiphospholipid syndrome (PAPS) patients are still very limited. <h3>Objectives</h3> To assess the long-term frequency of recurrences, organ damage, severe comorbidities, mortality and evolution in connective tissue disease (CTD) in PAPS patients. <h3>Methods</h3> Medical records of PAPS patients followed in 6 centers for ≥15 years were retrospectively reviewed. Chi square for categorical and Student t test for continuous variables were used. P&lt;0.05 was considered significant. <h3>Results</h3> One hundred and fifteen patients (88% females) followed between 1983 and 2014 with a mean age at diagnosis of 33 (±10) years and mean follow-up of 19 (±3.5) years were studied. Fifty-one patients (44%) had at least a thrombotic event during follow-up for a total of 75 events and an annual incidence of 3.5%. Thromboses were more frequent in patients with previous thrombotic history (p:0.002,OR:4.8, 95%CI:1.6–14.7). There was a tendency towards anticoagulant treatment being not protective against recurrences (p:0.063). Six patients (5%) had a catastrophic event. Fifty-two women had 87 pregnancies, successful in 78% of cases. Twenty-nine percent of patients had functional damage. Damage was significantly associated with a thrombotic history (p:0.004,OR:13.9,95%CI:1.8–288.4) and to arterial events (p&lt;0.001,OR:7.9,95%CI:2.7–24.3) especially stroke, but not to demographics, serology or treatment. Twenty-four major bleeding episodes were recorded in 18 patients, all on anticoagulants. Severe infections affected 6 patients (5%) with 1 fatality. A solid cancer was diagnosed in 8 patients (7%). One patient (1%) with a chronic bowel ischemia died for sepsis. Eleven percent of patients developed a CTD and 14% another autoimmune disease. <h3>Conclusions</h3> Despite therapy, a high proportion of patients experienced new thrombotic events,while pregnancy outcome was significantly improved. Organ damage developed in a significant proportion of patients and was associated with arterial events. The risk of evolution in CTD has to be considered. <h3>Disclosure of Interest</h3> None declared
Review of <i>MRI-Negative Epilepsy</i>
Authors: Beth Leeman-Markowski
Journal: JAMA Neurology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
Government must be clearer in its claims about NHS funding, says statistics watchdog
Authors: Gareth Iacobucci
Journal: BMJ (2016)

The UK government must be clearer and more precise in its claims about NHS and healthcare funding, the UK Statistics Authority has said.

The watchdog, which oversees the government’s use of official statistics, examined a repeated claim by the prime minister, Theresa May, that the government had provided £10bn (€11.75bn; $12.4bn) in extra funding for the health service. This followed complaints from the BMA and the Labour Party that this figure, which has also …
Effectiveness of an exercise programme on physical function in patients discharged from hospital following critical illness: a randomised controlled trial (the REVIVE trial)
Authors: Kathryn McDowell, Brenda O'Neill, Bronagh Blackwood, Chris Clarke, Evie Gardner, Paul Johnston, Michaeline Kelly, John McCaffrey, Brian Mullan, Sally Murphy, T John Trinder, Gavin Lavery, Daniel F McAuley, Judy M Bradley
Journal: Thorax (2016)

<h3>Objective</h3> To investigate the effectiveness of a 6-week exercise programme in patients discharged home following critical illness compared with standard care. <h3>Design</h3> Multicentre prospective phase II randomised controlled trial, with blinded outcome assessment after hospital discharge, following the 6-week intervention and at 6 months. <h3>Participants</h3> 60 patients (30 per group) aged ≥18 years, mechanically ventilated &gt;96 hours, and not in other rehabilitation, that is, cardiac or pulmonary rehabilitation programmes. Participants in the intervention group completed an individually tailored (personalised) exercise programme. <h3>Outcome measures</h3> Primary outcome measure was SF-36 physical functioning following the intervention. Secondary outcomes included a range of performance-based and patient-reported measures. <h3>Results</h3> Improvements in the primary outcome did not differ significantly between groups (mean difference (95% CI) 3.0 (−2.2 to 8.2), p=0.26). The intervention group showed significant improvement compared with the control group (mean difference (95% CI)) in SF-36 role physical (6.6 (0.73 to 12.5), p=0.03); incremental shuttle walk test (83.1 m (8.3 to 157.9), p=0.03); functional limitations profile (−4.8 (−8.7 to −0.9), p=0.02); self-efficacy to exercise (2.2 (0.8 to 3.7), p=0.01) and readiness to exercise (1.3 (0.8 to 1.9), p&lt;0.001). These improvements were not sustained at 6 months except readiness to exercise. Improvements in all other secondary outcome measures were not significant. <h3>Conclusions</h3> There was no statistically significant difference in the primary outcome measure of self-reported physical function following this 6-week exercise programme. Secondary outcome results will help inform future studies. <h3>Trial registration number</h3> NCT01463579. (results), https://clinicaltrials.gov/
Abstract 9925: Mixed Aortic Valve Disease: Natural History and Predictors of Adverse Events
Authors: Alexander Egbe, Joeseph Poterucha, Carole Warnes
Journal: Circulation (2015)

Objectives: To determine freedom from symptoms and adverse events (AE) defined as aortic valve replacement (AVR) or death in patients (pt) with mixed aortic valve disease (MAVD). Methods: Reviewed pt with moderate/severe MAVD (moderate/severe aortic stenosis and regurgitation) at the Mayo Clinic from 1994-2013. Only asymptomatic pt with normal ejection fraction (&gt;50%) and trileaflet aortic valves were included. Cox proportional-hazard models were used to determine predictors of AE. Event-free survival curves were generated with the Kaplan-Meier method. Results: We identified 213 pt (age=69±11 years, male=67%). AE occurred in 155 pt, and 71% of these AE occurred in moderate MAVD (peak velocity of 3 to 3.9 m/s). Mean follow-up was 10.1±3 years and time to AE was 2.9±2.1 years. Concomitant coronary artery bypass grafting (CABG) and/or aortic replacement during AVR was performed in 54/151 (36%). Early mortality was 0.7%. Freedom from AE was 30% and 15% at 5 and 10 years. Freedom from symptoms was 34% and 16% at 5 and 10 years. Predictors of AE were peak aortic velocity (hazard ratio [HR] 2.56 Confidence interval [CI] 2.24-2.93, p&lt;0.0001) for every 1m/s increase in peak velocity, and having severe stenosis or regurgitation at presentation (HR 2.92; CI 2.73-3.14, p=0.001). Conclusion: MAVD had high rate of AE and development of symptoms, even in a subset of pt with only moderate MAVD. Peak aortic velocity and severe MAVD at presentation predict AE. Figure Legend: pVel: peak velocity group 1: moderate aortic stenosis and regurgitation Group ≥2: severe aortic stenosis or regurgitation
Alemtuzumab and Rituximab for Therapy of Patents with Early Stage High Risk CLL: Report of a Planned Interim Analysis.
Authors: Clive S. Zent, Nancy D. Bone, Timothy G. Call, Tait D. Shanafelt, Susan M. Geyer, Charla R. Secreto, Diane F. Jelinek, Gordon W. Dewald, Neil E. Kay
Journal: Blood (2006)
WT1 Promotes Myeloid Development and Inhibits Lymphoid Development.
Authors: Aschwin L. Menke, G.H. J. Knops, P.C. M. Linssen, G. Nikoloski, A. Pennings, M. Philippens, G. Vierwinden, B. Lemmers, T. De Witte, B. A. Van der Reijden, J. H. Jansen
Journal: Blood (2004)
14q32 Abnormalities and 13q Deletions Are Common in Primary Systemic Amyloidosis Using Cytoplasmic Immunoglobulin Fluorescence In Situ Hybridization (cIg-FISH).
Authors: Alan H. Bryce, Rhett Ketterling, Morie Gertz, Steve Zeldenrust, Martha Lacy, Shaji Kumar, Suzanne Hayman, Francis Buadi, Phillip Greipp, John Lust, Vincent Rajkumar, Rafael Fonseca, David Dingli, Stephen Russell, Robert Kyle, Angela Dispenzieri
Journal: Blood (2007)
Combined Immuno-Chemotherapy (R-CHOP) Results in Significantly Superior Response Rates and Time to Treatment Failure in First Line Treatment of Patients with Lymphomplasmocytoid/ic Immunocytoma (LP-IC) - Results of a Prospective Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG).
Authors: Christian Buske, Martin H. Dreyling, Hartmut Eimermacher, Hans-Peter Boeck, Michael Pfreundschuh, Bernd Metzner, Roland Fuchs, Bernhard Woermann, Lorenz H. Truemper, Georg Hess, Hannes Wandt, Wolf-Dieter Ludwig, Ernst-Dietrich Kreuser, Joerg Schimke, H.-J. Weh, Stephan Schmitz, W. Schmiegel, Michael Unterhalt, Wolfgang Hiddemann
Journal: Blood (2004)